September 21, 2022 — Medtronic announced today that it has received Food and Drug Administration (FDA) approval for the treatment of non-left main bifurcation lesions utilizing the provisional ...
Stents Bifurcation
Patients with coronary artery disease where a lesion is located at a vessel bifurcation and extends into the side branch can be difficult to treat in a cath lab. The conventional treatment for bifurcations is to either used a single stent and leaving part of the vessel untreated, or use of two stents. Use of two stents can "cage" or "jail" the side branch vessel because of the stent struts in the main vessel. This might prevent future access to treat the side branch vessel. This channel offers news on bifurcation treatment strategies and development of dedicated side branch stents.
-
-
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is deployed in coronary vessels. The vendor made its debute on the expo floor of the ...
-
Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug-eluting stents (DES) for the treatment of bifurcation lesions. Bifurcation lesions account for approximately 20 percent of all percutaneous coronary interventions (PCI).[i] The Bifurcation Cohort, part of the RESOLUTE ONYX Post-Approval Study, will include patients with coronary artery disease (CAD) receiving the Resolute Onyx DES in sizes ranging from 2–5 mm in diameter.
-
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at Morristown Medical Center, part of Atlantic Health System, explains his experience with ...
September 21, 2022
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is ...
September 11, 2018
May 29, 2018 – Medtronic plc announced the initiation of a U.S. clinical study to assess the safety and efficacy of drug ...
May 29, 2018
January 18, 2018 – West Hills Hospital & Medical Center, a full-service acute care facility, announces the first ...
January 18, 2018
Philippe Genereux, M.D., co-director of the structural heart program at the Gagnon Cardiovascular Institute at ...
November 15, 2017
November 10, 2017 — Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portf ...
November 10, 2017
November 1, 2017 — The double kissing (DK) crush two-stent technique was associated with a lower rate of target lesion ...
November 01, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc. announced that the Tryton coronary Side Branch Stent was ...
September 21, 2017
March 31, 2017 — Tryton Medical Inc. recently announced that the first U.S. commercial case using the Tryton Side Branch ...
March 31, 2017
This video, provided by Tryton, demonstrates the implantation of the Tryton Side Branch Stent. It became the first ...
March 06, 2017
March 6, 2017 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) for the Tryton Side ...
March 06, 2017
October 28, 2016 – Tryton Medical Inc., a primary developer of stents to treat coronary bifurcation lesions, and
...
October 28, 2016
October 14, 2015 — Tryton Medical Inc. announced results from the pivotal Tryton Confirmatory Study confirming the ...
October 14, 2015
October 2, 2015 — Tryton Medical Inc. announced that results of a post hoc analysis of the pivotal Tryton Randomized ...
October 02, 2015
March 3, 2015 — Tryton Medical Inc. announced that results from the company’s pivotal clinical trial for the Tryton Side ...
March 03, 2015© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now